Organogenesis Holdings logo

Organogenesis HoldingsNASDAQ: ORGO

Profile

Sector:

Healthcare

Country:

United States

IPO:

05 January 2017

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$548.87 M
-59%vs. 3y high
67%vs. sector
-vs. 3y high
-vs. sector
-72%vs. 3y high
57%vs. sector
-59%vs. 3y high
27%vs. sector

Price

after hours | Wed, 20 Nov 2024 00:23:28 GMT
$4.14-$0.29(-6.55%)

Dividend

No data over the past 3 years
$115.18 M$106.93 M
$115.18 M$12.33 M

Analysts recommendations

Institutional Ownership

ORGO Latest News

Organogenesis Commends Final LCDs
globenewswire.com15 November 2024 Sentiment: POSITIVE

Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
globenewswire.com11 November 2024 Sentiment: POSITIVE

CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA).

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
globenewswire.com16 October 2024 Sentiment: POSITIVE

CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th.

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
globenewswire.com01 October 2024 Sentiment: POSITIVE

CANTON, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of “Dehydrated Amnion Chorion Membrane Versus Standard of Care for Diabetic Foot Ulcers: A Randomised Controlled Trial” in the Journal of Wound Care.

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
globenewswire.com04 September 2024 Sentiment: POSITIVE

CANTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences:

Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates
zacks.com08 August 2024 Sentiment: NEUTRAL

Organogenesis (ORGO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.04 per share a year ago.

Organogenesis Shares ReNu® Program Update
globenewswire.com08 August 2024 Sentiment: POSITIVE

CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced a development program update for ReNu®, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA).

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
globenewswire.com15 July 2024 Sentiment: POSITIVE

CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) --  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, August 8th.

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
globenewswire.com06 June 2024 Sentiment: POSITIVE

CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the Truist Securities MedTech Conference, which is being held at the InterContinental Boston in Boston, MA on Tuesday, June 18th. Management will participate in 1x1 meetings. There will be no formal presentation.

Why Organogenesis Holding Stock Plummeted by 18% Today
The Motley Fool01 March 2024 Sentiment: NEGATIVE

To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results.

  • 1(current)

What type of business is Organogenesis Holdings?

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

What sector is Organogenesis Holdings in?

Organogenesis Holdings is in the Healthcare sector

What industry is Organogenesis Holdings in?

Organogenesis Holdings is in the Drug Manufacturers - Specialty & Generic industry

What country is Organogenesis Holdings from?

Organogenesis Holdings is headquartered in United States

When did Organogenesis Holdings go public?

Organogenesis Holdings initial public offering (IPO) was on 05 January 2017

What is Organogenesis Holdings website?

https://organogenesis.com

Is Organogenesis Holdings in the S&P 500?

No, Organogenesis Holdings is not included in the S&P 500 index

Is Organogenesis Holdings in the NASDAQ 100?

No, Organogenesis Holdings is not included in the NASDAQ 100 index

Is Organogenesis Holdings in the Dow Jones?

No, Organogenesis Holdings is not included in the Dow Jones index

When was Organogenesis Holdings the previous earnings report?

No data

When does Organogenesis Holdings earnings report?

The next expected earnings date for Organogenesis Holdings is 28 February 2025